Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Quinoxalinediones for neurodegenerative/neurological disorders patented

Nov. 10, 1997

Takeda describes new melatonin agonists

Nov. 10, 1997

Ganaxolone shows promise in phase II epilepsy and migraine trials

Nov. 10, 1997

Apomorphine designated orphan drug

Nov. 7, 1997

Peripherally acting opioid analgesics described by Astra

Nov. 7, 1997

New neuroprotectants from HHS

Nov. 6, 1997

NIH scientists identify nicotinic receptor in hippocampus

Nov. 6, 1997

Melatonin evaluated for bipolar disorder

Nov. 6, 1997

U.S. clinical stroke trial supports efficacy and safety of citicoline

Nov. 6, 1997

Patient enrollment complete for phase II trial of memantine

Nov. 6, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 24, 2026.
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...
Other news to note for July 22, 2026
BioWorld
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Akari, Ashlins, Azurity, Eli Lilly, Engitix, Forge Biologics,...